Achilles Therapeutics plc (NASDAQ:ACHL – Get Rating) – Investment analysts at Oppenheimer issued their Q1 2024 EPS estimates for shares of Achilles Therapeutics in a research note issued on Tuesday, March 7th. Oppenheimer analyst M. Breidenbach anticipates that the company will post earnings per share of ($0.38) for the quarter. Oppenheimer has a "Market Perform" rating on the stock. The consensus estimate for Achilles Therapeutics' current full-year earnings is ($1.66) per share. Oppenheimer also issued estimates for Achilles Therapeutics' Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.39) EPS and Q4 2024 earnings at ($0.39) EPS.
Get Achilles Therapeutics alerts:Other analysts also recently issued reports about the stock. Chardan Capital dropped their price target on shares of Achilles Therapeutics from $17.00 to $12.00 in a research report on Wednesday. Piper Sandler dropped their target price on shares of Achilles Therapeutics from $10.00 to $8.00 and set an "overweight" rating on the stock in a report on Tuesday, December 6th.
Achilles Therapeutics Trading Down 4.3 %
NASDAQ ACHL opened at $1.00 on Thursday. Achilles Therapeutics has a one year low of $0.75 and a one year high of $3.45. The company has a 50-day simple moving average of $1.14 and a 200-day simple moving average of $1.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.43 and a current ratio of 10.43. The firm has a market capitalization of $38.96 million, a PE ratio of -0.55 and a beta of 0.98.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its stake in Achilles Therapeutics by 498.2% during the 4th quarter. Renaissance Technologies LLC now owns 484,733 shares of the company's stock worth $436,000 after purchasing an additional 403,700 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Achilles Therapeutics by 18.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,107,595 shares of the company's stock worth $4,763,000 after purchasing an additional 330,851 shares in the last quarter. Kettle Hill Capital Management LLC bought a new stake in Achilles Therapeutics during the 2nd quarter worth approximately $612,000. Millennium Management LLC bought a new stake in Achilles Therapeutics during the 4th quarter worth approximately $74,000. Finally, BlackRock Inc. increased its stake in Achilles Therapeutics by 25.5% during the 1st quarter. BlackRock Inc. now owns 266,657 shares of the company's stock worth $784,000 after purchasing an additional 54,225 shares in the last quarter. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Achilles Therapeutics Company Profile
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
Further Reading
- Get a free copy of the StockNews.com research report on Achilles Therapeutics (ACHL)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.